Beta-Amyloid (1-11) Research Applications, Clinical Value, a

Beta-Amyloid (1-11): Research Applications, Clinical Value, and Future Directions in Neurodegenerative Disease Studies
Introduction [Related: alpha amanitin]
Beta-Amyloid (1-11) is a synthetic peptide corresponding to the first eleven amino acids of the amyloid-beta (Aβ) protein, a key molecular player in the pathogenesis of Alzheimer’s disease (AD) and related neurodegenerative disorders. The Aβ peptide is generated by the sequential proteolytic cleavage of amyloid precursor protein (APP) by β- and γ-secretases, resulting in peptides of varying lengths, most commonly Aβ1-40 and Aβ1-42 (Selkoe & Hardy, 2016, Cell). The N-terminal fragment, Aβ(1-11), represents a critical region for understanding the initial aggregation, immunogenicity, and biochemical properties of the full-length peptide. [Related: exendin-4 antibody]
Mechanistically, Beta-Amyloid (1-11) is not itself neurotoxic or prone to aggregation in the same way as longer Aβ fragments, but it serves as a valuable research tool for dissecting the early events in Aβ processing, antibody recognition, and the development of diagnostic and therapeutic strategies. Its sequence (DAEFRHDSGYE) encompasses key epitopes recognized by several anti-amyloid antibodies and is involved in the initial steps of Aβ misfolding and oligomerization (Walsh et al., 2002, Nature). [Related: g418 sulfate]
This paper provides a comprehensive overview of Beta-Amyloid (1-11), focusing on its clinical value, research applications, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.
Clinical Value and Applications
Beta-Amyloid (1-11) has emerged as a critical reagent in the study of Alzheimer’s disease and other amyloidopathies. Its primary clinical value lies in its utility as a standard or control in immunoassays, epitope mapping, and the development of diagnostic antibodies. The peptide is widely used in enzyme-linked immunosorbent assays (ELISA), Western blotting, and immunohistochemistry to validate the specificity and sensitivity of anti-Aβ antibodies (Glenner & Wong, 1984, Biochem Biophys Res Commun).
Furthermore, Beta-Amyloid (1-11) is instrumental in the design of vaccines and immunotherapies targeting the N-terminal region of Aβ. Several preclinical studies have demonstrated that immunization with Aβ(1-11) or its conjugates can elicit robust antibody responses without inducing T-cell-mediated adverse effects, which are often associated with full-length Aβ immunization (Lemere et al., 2003, J Neurosci).
In addition, the peptide is used to study the proteolytic processing of APP and the generation of Aβ fragments, providing insights into the molecular mechanisms underlying amyloidogenesis. It also serves as a substrate for investigating the activity of Aβ-degrading enzymes and for screening small molecule inhibitors or modulators of Aβ aggregation (Haass & Selkoe, 2007, Nat Rev Mol Cell Biol).
Key Challenges and Pain Points Addressed
The study of amyloid-beta peptides is complicated by their propensity to aggregate, heterogeneity in length, and the presence of post-translational modifications. Full-length Aβ peptides (e.g., Aβ1-40, Aβ1-42) are notoriously difficult to handle due to their aggregation-prone nature, leading to variability in experimental outcomes and challenges in reproducibility (Walsh et al., 2002, Nature).
Beta-Amyloid (1-11) addresses several of these challenges:
1. **Reduced Aggregation:** The short length of Aβ(1-11) minimizes aggregation, allowing for more consistent and reproducible results in immunoassays and biochemical studies.
2. **Epitope Specificity:** As the N-terminal region contains key antibody epitopes, Aβ(1-11) enables precise mapping of antibody binding sites and the development of highly specific diagnostic reagents.
3. **Immunogenicity Studies:** The peptide can be used to generate immune responses focused on the N-terminal domain, reducing the risk of adverse T-cell responses seen with longer Aβ fragments.
4. **Standardization:** Aβ(1-11) serves as a reliable standard in quantitative assays, facilitating cross-laboratory comparisons and assay validation.
By providing a stable, well-characterized fragment of the Aβ sequence, Beta-Amyloid (1-11) enhances the reliability and interpretability of experimental data in AD research.
Literature Review
A growing body of literature supports the utility of Beta-Amyloid (1-11) in neurodegenerative disease research:
1. **Glenner & Wong (1984, Biochem Biophys Res Commun):** The authors first identified the amyloid-beta protein in Alzheimer’s disease brain tissue, highlighting the significance of the N-terminal region in amyloid plaque formation.
2. **Walsh et al. (2002, Nature):** This study demonstrated that soluble Aβ oligomers, rather than fibrillar aggregates, are the primary neurotoxic species in AD. The N-terminal region, including residues 1-11, was shown to play a role in oligomerization and antibody recognition.
3. **Lemere et al. (2003, J Neurosci):** The researchers reported that immunization with Aβ(1-11) conjugates elicited strong antibody responses in animal models without inducing encephalitis, suggesting a safer approach to Aβ-targeted immunotherapy.
4. **Haass & Selkoe (2007, Nat Rev Mol Cell Biol):** This review summarized the molecular mechanisms of Aβ generation and aggregation, emphasizing the importance of N-terminal fragments in the pathogenesis and diagnosis of AD.
5. **Kayed et al. (2003, Science):** The study introduced conformation-specific antibodies that recognize soluble Aβ oligomers, many of which bind to epitopes within the Aβ(1-11) region.
6. **Bard et al. (2000, Nat Med):** The authors demonstrated that passive immunization with anti-Aβ antibodies targeting the N-terminal region reduced amyloid plaque burden in transgenic mouse models.
7. **Schenk et al. (1999, Nature):** This seminal paper showed that active immunization with Aβ peptides reduced amyloid pathology in mice, with the N-terminal domain being a key immunogenic region.
Collectively, these studies underscore the central role of the Aβ(1-11) sequence in amyloid biology, antibody development, and immunotherapeutic strategies.
Experimental Data and Results
Experimental applications of Beta-Amyloid (1-11) span immunoassay development, antibody characterization, and immunogenicity studies:
1. **Immunoassay Standardization:** Aβ(1-11) is used as a calibration standard in ELISA kits for quantifying Aβ levels in biological samples. Studies have shown that using the N-terminal fragment improves assay specificity and reduces background noise compared to full-length peptides (Haass & Selkoe, 2007).
2. **Epitope Mapping:** Monoclonal antibodies generated against Aβ(1-11) exhibit high specificity for the N-terminal region, as demonstrated by Western blot and immunohistochemistry analyses (Kayed et al., 2003). These antibodies are critical for distinguishing between different Aβ species in tissue samples.
3. **Immunogenicity:** Preclinical studies in mice and rabbits have shown that immunization with Aβ(1-11) conjugated to carrier proteins induces robust antibody responses without T-cell-mediated toxicity (Lemere et al., 2003). This finding supports the use of Aβ(1-11) in vaccine development.
4. **Proteolytic Processing:** In vitro assays using Aβ(1-11) as a substrate have enabled the characterization of Aβ-degrading enzymes such as neprilysin and insulin-degrading enzyme, providing insights into the regulation of Aβ levels in the brain (Haass & Selkoe, 2007).
5. **Aggregation Studies:** While Aβ(1-11) itself does not form fibrils, it can inhibit the aggregation of longer Aβ peptides in vitro, suggesting a potential modulatory role in amyloidogenesis (Walsh et al., 2002).
These experimental results highlight the versatility and value of Beta-Amyloid (1-11) in both basic and translational research settings.
Usage Guidelines and Best Practices
To maximize the utility of Beta-Amyloid (1-11) in research applications, the following guidelines and best practices are recommended:
1. **Storage and Handling:** The peptide should be stored lyophilized at -20°C or below, protected from moisture and light. Reconstituted solutions should be aliquoted and stored at -80°C to prevent repeated freeze-thaw cycles.
2. **Preparation:** For immunoassays, dissolve the peptide in sterile, filtered water or buffer (e.g., PBS) to the desired concentration. For aggregation studies, ensure the use of freshly prepared solutions to avoid degradation.
3. **Assay Controls:** Use Aβ(1- Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 21 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11580655